Floatz logo

Cpx-351

Lymphoid Leukemia

H. Lee Moffitt Cancer Center and Research InstitutePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Lymphoid Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Ibrutinib
Loxo Oncology, Inc.
Phase 4BBB
Busulphan
Dartmouth-Hitchcock Medical Center
Phase 4BB
Pirtobrutinib
Loxo Oncology, Inc.
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 2BB

View all 50 →

Same molecule, other indications

Cpx-351 is also rated in:

therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
BB
Indicative ·
67 / 100
View asset →
Secondary Acute Myeloid LeukemiaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →